Marc Riedl on hereditary angioedema

About this episode

Professor Marc Riedl discusses trials of oral deucrictibant for treating hereditary angioedema attacks.

Professor Marc Riedl joins us to discuss two trials testing oral deucrictibant for hereditary angioedema attacks: one testing deucrictibant as on-demand therapy to treat attacks and the other testing deucrictibant for prophylaxis of attacks. Click here to read the full articles: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00341-2/fulltext https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(26)00004-9/fulltext Continue this conversation on social! Follo...

People in this episode

Guest: Marc Riedl

Topics covered

• hereditary angioedema
• deucrictibant
• clinical trials
• on-demand therapy
• prophylaxis

Keywords

• hereditary angioedema
• deucrictibant
• clinical trials
• therapy
• prophylaxis

Mentioned in this episode

Organizations: The Lancet

Products: deucrictibant

More episodes of The Lancet Haematology in conversation with

• Carmelo Gurnari on the development of recommendations from the EBMT Practice Harmonisation and Guidelines Committee · June 4, 2026 · 17 min
• Penelope Stein on acute prophyria · April 28, 2026 · 16 min
• Julio Delgado and Valentín Ortiz-Maldonado (Spanish version) · March 4, 2026 · 13 min
• Julio Delgado and Valentín Ortiz-Maldonado · March 4, 2026 · 12 min
• Erica Kaye and Dylan Graetz discuss expert recommendations for the conduct and appraisal of qualitative research in haematology · February 4, 2026 · 20 min
• Presented at ASH: API-CAT post-hoc analysis on predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE · December 31, 2025 · 10 min